Compare STKE & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STKE | MAIA |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.9M | 69.2M |
| IPO Year | 2021 | 2022 |
| Metric | STKE | MAIA |
|---|---|---|
| Price | $1.31 | $1.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 442.0K | ★ 565.0K |
| Earning Date | 01-28-2027 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.85 | $0.87 |
| 52 Week High | $3.95 | $3.19 |
| Indicator | STKE | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 33.53 |
| Support Level | $1.00 | N/A |
| Resistance Level | $1.37 | $1.47 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 9.02 | 9.37 |
Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.